Desmopressin  	Desmopressin  	 JJ	B-NP
testing  	testing  	 NN	I-NP
in  	in  	 IN	O
children  	children  	 NNS	O
with  	with  	 IN	O
von  	von  	 NNP	B-NP
Willebrand  	Willebrand  	 NNP	I-NP
syndrome  	syndrome  	 NN	I-NP
in  	in  	 IN	O
haemostaseologic  	haemostaseologic  	 JJ	B-NP
centers  	centers  	 NNS	I-NP
of  	of  	 IN	I-NP
Saxonia 	Saxonia 	 NNP	I-NP
,  	,  	 ,	O
Saxonia-Anhalt  	Saxonia-Anhalt  	 JJ	B-NP
and  	and  	 CC	O
Thuringia  	Thuringia  	 NNP	B-NP
The  	The  	 DT	O
influence  	influence  	 NN	O
of  	of  	 IN	O
desmopressin  	desmopressin  	 NN	B-NP
on  	on  	 IN	O
hemostasis  	hemostasis  	 NN	B-NP
is  	is  	 VBZ	O
mediated  	mediated  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
release  	release  	 NN	O
of  	of  	 IN	O
von  	von  	 NNP	B-NP
Willebrand  	Willebrand  	 NNP	I-NP
factor  	factor  	 NN	I-NP
and  	and  	 CC	O
of  	of  	 IN	O
coagulation  	coagulation  	 JJ	B-NP
factor  	factor  	 NN	I-NP
VIII  	VIII  	 NN	I-NP
from  	from  	 IN	O
vascular  	vascular  	 JJ	B-NP
endothelium 	endothelium 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
necessity  	necessity  	 NN	O
of  	of  	 IN	O
testing  	testing  	 VBG	O
desmopressin  	desmopressin  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
on  	on  	 IN	O
hemostasis  	hemostasis  	 NN	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
matter  	matter  	 NN	O
of  	of  	 IN	O
controversy  	controversy  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
performance  	performance  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
test  	test  	 NN	O
is  	is  	 VBZ	O
not  	not  	 RB	O
yet  	yet  	 RB	O
standardized 	standardized 	 JJ	O
.  	.  	 .	O
For  	For  	 IN	O
this  	this  	 DT	O
reason  	reason  	 NN	O
the  	the  	 DT	O
desmopressin  	desmopressin  	 JJ	B-NP
tests  	tests  	 NNS	I-NP
in  	in  	 IN	O
114  	114  	 CD	O
children  	children  	 NNS	O
with  	with  	 IN	O
von  	von  	 NNP	B-NP
Willebrand  	Willebrand  	 NNP	I-NP
syndrome  	syndrome  	 NN	I-NP
( 	( 	 -LRB-	O
type  	type  	 NN	O
1 	1 	 CD	O
,  	,  	 ,	O
n=98 	n=98 	 NNP	O
;  	;  	 :	O
type  	type  	 CD	O
2A 	2A 	 CD	O
,  	,  	 ,	O
n=12 	n=12 	 NNP	O
;  	;  	 :	O
type  	type  	 CD	O
2M 	2M 	 CD	O
,  	,  	 ,	O
n=2 	n=2 	 NNP	O
;  	;  	 :	O
type  	type  	 CD	O
2N 	2N 	 CD	O
,  	,  	 ,	O
n=2 	n=2 	 CD	O
)  	)  	 -RRB-	O
carried  	carried  	 VBD	O
out  	out  	 RP	O
in  	in  	 IN	O
7  	7  	 CD	O
paediatric  	paediatric  	 CD	B-NP
haemostaseologic  	haemostaseologic  	 CD	I-NP
centers  	centers  	 NNS	I-NP
were  	were  	 VBD	O
retrospectively  	retrospectively  	 JJ	O
analyzed 	analyzed 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
desmopressin  	desmopressin  	 NN	B-NP
was  	was  	 VBD	O
assessed  	assessed  	 VBN	O
using  	using  	 VBG	O
defined  	defined  	 VBN	B-NP
response  	response  	 NN	I-NP
criteria 	criteria 	 NNS	I-NP
.  	.  	 .	O
As  	As  	 RB	O
expected 	expected 	 VBN	O
,  	,  	 ,	O
the  	the  	 DT	O
test  	test  	 NN	B-NP
performance  	performance  	 NN	I-NP
showed  	showed  	 VBD	O
a  	a  	 DT	O
wide  	wide  	 JJ	O
variation  	variation  	 NN	O
among  	among  	 IN	O
the  	the  	 DT	O
centers 	centers 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
99  	99  	 CD	O
children  	children  	 NNS	B-NP
desmopressin  	desmopressin  	 NN	I-NP
was  	was  	 VBD	O
given  	given  	 VBN	O
intravenously  	intravenously  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
short  	short  	 JJ	O
infusion  	infusion  	 NN	O
at  	at  	 IN	O
a  	a  	 DT	O
dosage  	dosage  	 NN	O
ranging  	ranging  	 VBG	O
from  	from  	 IN	O
0.25  	0.25  	 CD	O
to  	to  	 TO	O
0.41  	0.41  	 CD	O
microg 	microg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg  	kg  	 NNS	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
15  	15  	 CD	O
intranasally  	intranasally  	 NN	O
at  	at  	 IN	O
an  	an  	 DT	O
absolute  	absolute  	 JJ	O
dose  	dose  	 NN	O
of  	of  	 IN	O
40  	40  	 CD	O
to  	to  	 TO	O
300  	300  	 CD	O
microg 	microg 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
points  	points  	 NNS	O
of  	of  	 IN	O
time  	time  	 NN	O
for  	for  	 IN	O
blood  	blood  	 NN	O
taking  	taking  	 VBG	O
after  	after  	 IN	O
desmopressin  	desmopressin  	 JJ	B-NP
application  	application  	 NN	I-NP
ranged  	ranged  	 VBD	O
from  	from  	 IN	O
0.5  	0.5  	 CD	O
to  	to  	 TO	O
12  	12  	 CD	O
h 	h 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
absent  	absent  	 JJ	O
desmopressin  	desmopressin  	 JJ	B-NP
response  	response  	 NN	I-NP
in  	in  	 IN	O
7  	7  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
6 	6 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
the  	the  	 DT	O
partial  	partial  	 JJ	O
response  	response  	 NN	O
in  	in  	 IN	O
15  	15  	 CD	O
indicate  	indicate  	 VBP	O
the  	the  	 DT	O
necessity  	necessity  	 NN	O
of  	of  	 IN	O
testing  	testing  	 VBG	O
desmopressin  	desmopressin  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
before  	before  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
use 	use 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
application  	application  	 NN	O
of  	of  	 IN	O
desmopressin  	desmopressin  	 NN	B-NP
was  	was  	 VBD	O
well  	well  	 RB	O
tolerated  	tolerated  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
patients 	patients 	 NNS	O
.  	.  	 .	O
